The firm will use the proceeds to continue developing its Proteograph platform, build its proteomic database, and develop liquid biopsy products for early disease detection.
The firm is applying the isolation tool in cellular therapy for oral cancer by administering a biomarker via bioengineered exosomes to reverse cancer progression.
Presentations at this month's ASCO meeting demonstrated how efforts are advancing to determine when and how longitudinal ctDNA testing will be useful for oncologists.
The firm said it can detect circulating tumor DNA with a mutational allele frequency of 0.001 percent, enabled by digital PCR and the firm's proprietary chemistry.
The company is offering around 7.9 million shares of common stock at a price of $17 per share and is granting the underwriters an option to buy an additional 1.2 million shares.
The firm is in the midst of a clinical trial called NOVA to compare its circulating-tumor DNA-based Colvera test to DiaSorin's carcinoembryonic antigen assay.
Exact Sciences and the Mayo Clinic are working to develop a blood test for pancreatic cancer that might be able to diagnose patients with early-stage disease.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
The University of Michigan researchers aim to commercialize the Hydro-Seq microfluidic platform, which isolates and prepares single circulating tumor cells for RNA sequencing.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
